Literature DB >> 25035144

Triple jeopardy for Hodgkin lymphoma survivors?

Lindsay M Morton1.   

Abstract

In this issue of Blood, van Eggermond et al demonstrate that Hodgkin lymphoma survivors who develop a second malignancy have increased risk of developing yet a third malignancy.

Entities:  

Mesh：

Year:  2014        PMID： 25035144      PMCID： PMC4102703          DOI： 10.1182/blood-2014-05-571646

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Late effects in the era of modern therapy for Hodgkin lymphoma.

Authors:  David C Hodgson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Wei Liu; Wendy Leisenring; Yutaka Yasui; Sue Hammond; Smita Bhatia; Joseph P Neglia; Marilyn Stovall; Deokumar Srivastava; Leslie L Robison
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma.

Authors:  David C Hodgson; Ethel S Gilbert; Graça M Dores; Sara J Schonfeld; Charles F Lynch; Hans Storm; Per Hall; Froydis Langmark; Eero Pukkala; Michael Andersson; Magnus Kaijser; Heikki Joensuu; Sophie D Fosså; Lois B Travis
Journal:  J Clin Oncol       Date:  2007-03-19       Impact factor: 44.544

4.  Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.

Authors:  Timothy Best; Dalin Li; Andrew D Skol; Tomas Kirchhoff; Sarah A Jackson; Yutaka Yasui; Smita Bhatia; Louise C Strong; Susan M Domchek; Katherine L Nathanson; Olufunmilayo I Olopade; R Stephanie Huang; Thomas M Mack; David V Conti; Kenneth Offit; Wendy Cozen; Leslie L Robison; Kenan Onel
Journal:  Nat Med       Date:  2011-07-24       Impact factor: 53.440

5.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Authors:  Lois B Travis; Mary Gospodarowicz; Rochelle E Curtis; E Aileen Clarke; Michael Andersson; Bengt Glimelius; Timo Joensuu; Charles F Lynch; Flora E van Leeuwen; Eric Holowaty; Hans Storm; Ingrid Glimelius; Eero Pukkala; Marilyn Stovall; Joseph F Fraumeni; John D Boice; Ethel Gilbert
Journal:  J Natl Cancer Inst       Date:  2002-02-06       Impact factor: 13.506

6.  Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.

Authors:  Anna M van Eggermond; Michael Schaapveld; Pieternella J Lugtenburg; Augustinus D G Krol; Jan Paul de Boer; Josée M Zijlstra; John M M Raemaekers; Leontien C M Kremer; Judith M Roesink; Marieke W J Louwman; Berthe M P Aleman; Flora E van Leeuwen
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

7.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Authors:  Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

8.  Stomach cancer risk after treatment for hodgkin lymphoma.

Authors:  Lindsay M Morton; Graça M Dores; Rochelle E Curtis; Charles F Lynch; Marilyn Stovall; Per Hall; Ethel S Gilbert; David C Hodgson; Hans H Storm; Tom Børge Johannesen; Susan A Smith; Rita E Weathers; Michael Andersson; Sophie D Fossa; Michael Hauptmann; Eric J Holowaty; Heikki Joensuu; Magnus Kaijser; Ruth A Kleinerman; Frøydis Langmark; Eero Pukkala; Leila Vaalavirta; Alexandra W van den Belt-Dusebout; Joseph F Fraumeni; Lois B Travis; Berthe M Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

Review 9.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.